Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics.
Clicks: 348
ID: 86251
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
3.0
/100
10 views
10 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
For many years, the controlled delivery of therapeutic compounds has been a matter of great interest in the field of nanomedicine. Among the wide amount of drug nanocarriers, magnetic iron oxide nanoparticles (IONs) stand out from the crowd and constitute robust nanoplatforms since they can achieve high drug loading as well as targeting abilities stemming from their remarkable properties (magnetic and biological properties). These applications require precise design of the nanoparticles regarding several parameters which must be considered together in order to attain highest therapeutic efficacy.This short review presents recent developments in the field of cancer targeted drug delivery using magnetic nanocarriers as drug delivery systems.The design of nanocarriers enabling efficient delivery of therapeutic compounds toward targeted locations is one of the major area of research in the targeted drug delivery field. By precisely shaping the structural properties of the iron oxide nanoparticles, drugs loaded onto the nanoparticles can be efficiently guided and selectively delivered toward targeted locations. With these goals in mind, special attention should be given to the pharmacokinetics and in vivo behavior of the developed nanocarriers.
| Reference Key |
vangijzegem2019magneticexpert
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Vangijzegem, Thomas;Stanicki, Dimitri;Laurent, Sophie; |
| Journal | expert opinion on drug delivery |
| Year | 2019 |
| DOI |
10.1080/17425247.2019.1554647
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.